Subscribe
Facebook Twitter Instagram Youtube

International Association of Hepatitis Task Forces (IAHTF)

Email

wmremak@pacbell.net

Phone

T: +1 707 7734922

Web

http://www.nahtf.org/

Address

Miller Depot, 320 West Cummings, PO Box 66 Miller AA 68858 United States of America
About International Association of Hepatitis Task Forces (IAHTF)

We provide support, networking for developing, and existing community hepatitis task forces, reinforcing regional efforts for better access to care for those affected and deliver greater tools to encourage the medical and scientific community throughout the world.

Mission Statement
Our mission is to provide support, networking for developing, and existing community viral hepatitis coordinated activities, reinforcing regional efforts for better access to care for those affected and deliver greater tools to encourage the medical and scientific community throughout the world.

Initatives of the IAHTF

  • Advocacy for patients with hepatitis B and C worldwide
  • Enhance access to care and drive public health reform globally
  • Health Equity
  • Linkage to Care
  • Global Communication to foster understanding
  • Patient Empowerment
  • Unification of Voices
  • De-stigmatization
  • Building Capacity
  • Resource development
  • Transforming cultural competency to driving outcomes
  • Disparity reduction
  • Knowledge enhancement through education and public awareness
  • Leveraging technology in care
  • Driving innovation and research for elimination target
  • Stakeholder inclusion that puts the patient first
  • Legislative weigh in as a unified body on policy issues
  • Addressing co-morbidity's
  • Going to the root of social determinants

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)
Confirm consent(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close